Clinical Trial Search

Primary: Percentage of Participants Achieving HBV DNA < 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) - — 91.0; 95.0; 91.9; 95.0 percentage of participants

Primary: The Primary Outcome Variable Was Probing Depth. — 4.57; 4.18; 3.12; 2.91 mm — p=<0.01

Primary: Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes — 137 Participants

Primary: Decreased Minute Ventilation — 0.736; 0.764 percentage of baseline — p=<0.0001

Primary: Peak And Trough Concentrations Of Eculizumab In Serum At Week 12 — 192.5; 425.4 μg/mL

Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )

Primary: Differences in Glycemic Control — 171; 159; 126; 132 mg/dl

Primary: Visual Analog Scale (VAS) Pain Scores at 6 Hours After Treatment — 0.6; 2.6; 1.0; 2.0 scores on a scale — p=0.04

Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — 2.44; 2.49; 1.01; 2.37 Score on a scale — p=<.0001

Primary: Time to First Relapse During the Double-Blind Treatment Period (DBTP) — NA; NA days — p=0.0212

Primary: Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO — 14; 16 Participants

Primary: Safety and Tolerability of Combined Exercise and Regadenoson Stress — 0; 3; 3; 0 Participants

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Intraocular Pressure — 19.7; 18.1; 19.1; 18.8 mmHg

Primary: Time to Ambulation — 480; 316 minutes — p=<0.001